Skip Navigation


Annals of Oncology Advance Access originally published online on April 11, 2008
Annals of Oncology 2008 19(7):1213-1215; doi:10.1093/annonc/mdn157
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/7/1213    most recent
mdn157v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Del Mastro, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Del Mastro, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

editorials

The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients

L. Del Mastro*

Oncologia Medica A, Istituto Nazionale per la Ricerca sul, Cancro, L.go R. Benzi 10, 16132 Genoa, Italy

* (E-mail: lucia.delmastro@istge.it)

The first 10% of the full text of this article appears below.

Available adjuvant treatments for premenopausal endocrine-responsive breast cancer patients include chemotherapy, tamoxifen and luteinizing hormone-releasing hormone (LH-RH) agonists.

In women younger than 50 years and estrogen receptor-positive (ER+) tumors, adjuvant polychemotherapy is associated with an annual reduction in mortality of 31% [standard error (SE) = 0.10]. In this subgroup of patients, tamoxifen is also very effective with an annual reduction in mortality ranging from 39% (SE = 0.12) in women younger than 40 years to 24% in women aged 40–49 years [1]. A recent meta-analysis showed that LH-RH agonists did not significantly reduce death after recurrence neither when used as the only systemic treatment [17.8% relative reduction, 95% confidence interval (CI) –52.8 to 42.9; P = 0.49] nor when added to tamoxifen (15.9%; 95% CI –40.7 to 19.4; P = 0.33) or to chemotherapy (12.9%; 95% CI –26.5 to 3.2; P = . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
V. H. C. Bramwell, K. I. Pritchard, D. Tu, K. Tonkin, H. Vachhrajani, T. A. Vandenberg, J. Robert, A. Arnold, S. E. O'Reilly, B. Graham, et al.
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)
Ann. Onc., July 23, 2009; (2009) mdp326v1.
[Abstract] [Full Text] [PDF]